PPIDT00068

Drug Information
NameTositumomab
SequenceQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB00081
Typebiotech
IndicationFor treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)

Dosage Forms
Form Route Strength
Kit Intravenous
Injection Intravenous
0.61 mCi/1mL
Injection Intravenous
5.6 mCi/1mL
Kit; solution Intravenous
14 mg / mL
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P11836 MS4A1 B-lymphocyte antigen CD20 Homo sapiens antibody Link
target P31994 FCGR2B Low affinity immunoglobulin gamma Fc region receptor II-b Homo sapiens unknown Link